May 27, 2026

Biologics Commonly Used in Cutaneous Crohn Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn disease.

Conexiant

May 27, 2026

Biologics Commonly Used in Cutaneous Crohn Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn disease.

Conexiant

May 20, 2026

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Conexiant

May 13, 2026

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Conexiant

May 07, 2026

Tirzepatide's Surprising Skin Side Effect

A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.

Conexiant

April 28, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Conexiant

April 28, 2026

Parallel Ridge Pattern Signals Acral Melanoma Risk

Meta-analysis supports multi-feature dermoscopic evaluation.

Conexiant

April 28, 2026

Cutaneous Rhabdomyosarcoma May Mask Melanoma

Molecular and epigenetic profiling suggested most tumors in a rare cutaneous sarcoma cohort were better classified as transdifferentiated melanoma.

Conexiant

April 24, 2026

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

Conexiant

April 24, 2026

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Conexiant